Introduction
Colorectal cancer is the third leading cause of cancer death for men and women in the United States. Of the nearly 140,000 new cases each year, 20 % will have metastatic disease at presentation. [1] Since the FDA approval of bevacizumab in 2004, antiangiogenic therapy has played a critical role in the therapeutic management of metastatic colorectal cancer (mCRC). With recent advances in therapeutics for mCRC, overall survival from the time of diagnosis is now approaching 3 years. [2] .
Bevacizumab is a recombinant humanized monoclonal antibody, which targets the vascular endothelial growth factor (VEGF)-A ligand. The use of bevacizumab for patients with mCRC provides progression-free survival (PFS) and overall survival (OS) advantages when combined with cytotoxic chemotherapy in the first and second line settings. [3] [4] [5] Further studies have demonstrated that continuation of bevacizumab beyond first-line progression into second line therapy is associated with a survival benefit. [6] Similar survival benefit was seen with the fusion protein aflibercept (a fusion protein targeting VEGF-A, VEGF-B, and placental growth factor [PlGF] ) as well as with ramucirumab, a monoclonal antibody against VEGFR-2, when combined with FOLFIRI in the second-line setting after receiving a bevacizumab-containing regimen. [7, 8] Despite improvements in outcomes with continuing antiangiogenesis inhibition with multiple lines of cytotoxic chemotherapy, these effects are temporary and eventually resistance to systemic therapy develops.
Several studies have provided insights into potential mechanisms o f primary and seconda ry resistance to antiangiogenesis therapy. Inhibition of the VEGF receptor-2 (VEGFR-2) leads to upregulation of other pro-angiogenic factors beyond VEGF. [9, 10] Casanovas et al. demonstrated inhibition of VEGFR-2 lead to a hypoxia driven upregulation of members of the fibroblast growth factor (FGF) family, FGF-1 and FGF-2 in a mouse model of pancreatic islet cell carcinoma. [11] Kopetz et al. also demonstrated increased levels of circulating proangiogenic factors including FGF and platelet-derived growth factor (PDGF) in patients prior to progression while on treatment with bevacizumab. [12] Since sorafenib is a multikinase inhibitor targeting several serine/threonine and tyrosine kinases including all VEGF-receptors, Raf, PDGF receptor B, and FGF receptor 1, it was postulated that the combination of bevacizumab and sorafenib might provide a more complete blockade of proangiogenic pathways as well as inhibit mechanisms of bevacizumab resistance.
Clinical data also suggest sorafenib plus bevacizumab has the potential to be an active regimen in mCRC. After a phase I trial demonstrated substantial activity of sorafenib plus bevacizumab in patients with various malignancies, [13] the combination was evaluated in the last-line setting in patients with mCRC in the N054C trial. [14] Patients received bevacizumab (5 mg/kg) on day 1 and sorafenib (200 mg twice daily), on days 1-5 and 8-12 of a two-week cycle. The median PFS was 3.1 months (95 % CI: 2.7-4.0 months). Four patients experienced a partial response (PR) and 48 patients had stable disease (SD), which equates to disease control (PR or SD) in 63 % of patients. The median OS was 6.7 months (95 % CI: 4.5-8.9 months). The PFS of 3.1 months is comparable to the efficacy of EGFR antibodies as salvage therapy in KRAS wild-type colorectal cancer (PFS of 3.8 months in the cetuximab arm versus 1.9 months with BSC). [15] .
We felt the observed activity of bevacizumab and sorafenib in N054C warranted further development in mCRC clinical trials by combining the combination with FOLFIRI. The sorafenib/bevacizumab/FOLFIRI treatment regimen could potentially serve as an option for second-line therapy in KRAS mutant mCRC. The purpose of this phase I trial was to establish the maximum tolerable dose (MTD) of FOLFIRI, bevacizumab, and sorafenib for patients with advanced GI malignancies.
Patients and methods

Patient selection
Patients ≥18 years of age with metastatic and/or unresectable gastrointestinal malignancies who were candidates for irinotecan-based therapy were eligible for this study. Patients must have met the following criteria: ECOG Performance Status (PS) 0 or 1, able to provide informed consent, willing to return to Mayo Clinic for follow up, life expectancy ≥84 days (3 months), and women of child bearing potential must have had a negative pregnancy test ≤7 days prior to registration. Measurable disease was required. Patients who had received irinotecan previously were allowed if the treating physician felt further treatment with irinotecan-based therapy was appropriate. Prior treatment with sorafenib was not allowed. Patients with inadequately controlled hypertension, recent cardiovascular or thrombotic events, bleeding diathesis, brain metastasis, history of abdominal fistula, recent gastrointestinal perforation or intra-abdominal abscess, and other active malignancies were excluded.
Patients could not have received chemotherapy ≤14 days prior to registration, immunotherapy ≤28 days prior to registration, radiation therapy ≤28 days prior to registration, or radiation to >25 % of bone marrow. Patients who had not fully recovered from reversible effects of prior chemotherapy were ineligible. Women who are pregnant or nursing and persons of childbearing potential who are unwilling to employ adequate contraception were not allowed on the study. This study was approved by the Mayo Clinic Institutional Review Board (IRB). Each participant signed an IRB-approved, protocol-specific informed consent in accordance with federal and institutional guidelines.
Treatment
This trial utilized a standard 3 + 3 dose escalation/deescalation design with standard doses of FOLFIRI and bevacizumab combined with escalating doses of sorafenib (Table 1) . Dose level 1 consisted of sorafenib 200 mg by mouth daily on days 3-7 and 10-14; dose level 2 consisted of 200 mg by mouth twice daily on days 3-6 and 10-13; and dose level 3 consisted of 200 mg by mouth twice daily on days 3-7 and 10-14. Standard doses of FOLFIRI (irinotecan 180 mg/m 2 day 1, leucovorin 400 mg/m2 day 1, 5-fluorouracil (FU) bolus 400 mg/m 2 day 1, 5-FU infusion 2400 mg/m 2 over 46 h) plus bevacizumab 5 mg/kg on day 1 were given on a 14-day cycle. Standard antiemetic prophylaxis, as well as treatment of diarrhea and cholinergic syndrome, was given per institutional guidelines. The administration of sorafenib starting on day 3 was chosen to reduce potential drug interactions between irinotecan and sorafenib, which are both metabolized through the CYP34A pathway. [16, 17] Prior pharmacokinetic studies show sorafenib at a dose of 200 mg twice daily continuously dosing leads to drug concentration levels that cover inhibition of Flt-3, RET, KIT, VEGFR-2, VEGFR-3, and PDGRF-b based upon biochemical and cellular IC 50 data. [18, 19] .
Patients were treated on the clinical trial until they chose to discontinue treatment for any reason, experienced progressive disease (PD), or had unacceptable adverse events.
Patient evaluation
Patients were evaluated every cycle for treatment adherence and adverse events. Three patients were treated at each dose level and observed for a minimum of 28 days (two full cycles) to assess toxicities before new patients were treated. Doses were not escalated in any individual patient. Dose-limiting toxicity (DLT) was defined as an adverse event at least possibly related to the study medication and meeting one the following criteria per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: ≥ grade 4 anemia, grade 4 neutrophil count decrease, grade 4 platelet count decrease, serum creatinine ≥2 times baseline or ≥2 times the upper limit of normal if baseline is < the upper limit of normal, or any ≥ grade 3 nonhematologic event. Grade 3 or greater nausea, vomiting, or diarrhea was considered dose-limiting if maximal supportive treatment was utilized.
If a patient failed to complete the initial course of therapy (defined as drug administration and 2 weeks observation) for reasons other than dose-limiting toxicity defined adverse events, the patient was regarded as uninformative in regard to the primary study goal and an additional patient was treated at that current dose level; however, all toxicity information was utilized in the analysis.
Disease assessment
Imaging studies for disease assessment were performed within 4 days before planned treatment every 6 weeks. Response and progression was evaluated in this study using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1). [20] .
Statistical considerations
The goal of this study was to determine the maximum tolerable dose (MTD) of the combination of FOLFIRI, bevacizumab, and sorafenib. Secondary goals were to assess the safety of FOLFIRI plus sorafenib plus bevacizumab, to assess the feasibility of the proposed combination, to evaluate the response rate, and to identify any activity of the proposed combination. This single-arm Phase I study used the standard cohort 3 + 3 design. MTD is defined as the dose level below the lowest dose that induces DLT in at least one-third of patients.
Results
Patient accrual
Data for this report was summarized using data as of 05/20/ 2015. Patient characteristics are noted in Table 2 . Seventeen patients were enrolled between August 18, 2011 and February 22, 2013. Out of the 17 patients, 6 are female and 11 are male with median age of 56 years (range 32 to 81). Tumor types represented included 14 patients with mCRC, 2 patients with metastatic esophageal adenocarcinoma, and 1 patient with metastatic gall bladder adenocarcinoma. As of 05/20/2015, sixteen patients are off treatment; six progressed on study, four patients refused further treatment, four discontinued treatment due to AEs/side effects, one switched to alternative treatment, and one discontinued treatment due to other reason. A median 14 cycles was administered on the trial (range 1-78). Three patients remained on study for greater than 1 year. One patient remains on study at cycle 78.
Determination of recommended phase II dose
Fifteen patients were evaluable for DLT evaluation. Four patients were enrolled at dose level 1 (1 experienced dehydration and hospitalization prior to first dose of sorafenib and was replaced). No DLTs in remaining 3 patients in dose level 1. There were no DLTs in 3 patients enrolled at dose level 2. The first 4 patients at dose level 3 had no DLTs (one replaced due to incorrect treatment procedure). Two patients experienced DLTs in the second cohort at dose level 3. (One patient experienced grade 3 hypophosphatemia, and the other patient experienced grade 3 dehydration and diarrhea). There were no patients who experienced DLT in the second cohort of dose level 2. Therefore, the MTD was determined to be dose level 2: FOLFIRI + bevacizumab + sorafenib 200 mg bid, days 3-6, 10-13.
Adverse event summary, across cohorts
Thirteen (76.5 %) of patients experienced adverse events ≥ grade 3 that were at least possibly related to treatment ( Table 3 ). The majority of the adverse events were expected side effects of FOLFIRI plus bevacizumab as well as sorafenib, with the exception of pericardial effusion and tamponade in a patient who had prior radiation therapy for esophageal adenocarcinoma.
Outcome measures
Fifteen patients were eligible for response evaluation. Outcome measures according to disease type and prior therapies received are listed in Table 4 . Four patients (26.7 %) had a PR, 8 patients (53.5 %) had SD as best response, and 1 patient had PD as best response (disease control rate of 80 %). Seven of 15 patients (47 %) had disease control for ≥6 months. Two patients in dose level 3 were not evaluable; one discontinued treatment before disease assessment was performed due to hospitalization, and one patient stopped drug due to difficulty swallowing.
Among the 4 patients with PR, 2 were patients with CRC who had not received prior irinotecan based therapy. The other 2 responders were patients with metastatic esophageal cancer who both had been previously treated with oxaliplatin, irinotecan, and a fluoropyrimidine.
Five patients that enrolled on the study are deceased, 10 patients are alive with disease, one patient is alive with disease status unknown, and one patient continues to receive treatment on the trial.
Discussion
The recommended phase II dose from this study is standard doses of FOLFIRI and bevacizumab combined with sorafenib 200 mg bid, on days 3-6 and 10-13 of a 14 day cycle. This study demonstrates that dual VEGF inhibition with bevacizumab and sorafenib added to standard chemotherapy is safe and feasible for patients with advanced GI malignancies. Among the evaluable patients, PR was noted in 4 patients (26.7 %) and 8 patients (53.5 %) had SD with an overall disease control rate of 80 %. Three patients had prolonged disease stability, with greater than one year on the clinical trial.
Among all patients, 13 (76.5 %) of patients experienced ≥ grade 3 adverse events that were at least possibly related to treatment. Most toxicities were similar to those expected with FOLFIRI plus bevacizumab. This level of toxicity is comparable to results of other clinical trials containing irinotecan, 5-fluorouracil and bevacizumab. For instance, in the pivotal trial that established bevacizumab in the first-line treatment of mCRC, 84.9 % of patients in the irinotecan, bolus 5-FU and bevacizumab arm experienced a grade 3 or 4 adverse event.
[4] In the study which evaluated FOLFIRI plus bevacizumab in the second-line setting after prior bevacizumab-containing first-line therapy, 64 % percent of patients had a ≥ grade 3 adverse event. [6] Additionally, 9 of the 17 enrolled patients (53 %) remained on our study for ≥6 months, further attesting to the tolerability of the regimen for a select group of patients.
Because this trial was intended to determine the MTD and evaluate safety, a heterogeneous patient population was enrolled, and therefore, no comparisons with other trials can be made on survival outcomes. However, the duration of disease control in several patients showed some intriguing results indicating that there may be a select group of patients that could benefit from dual VEGF inhibition in combination with chemotherapy. For instance, several patients had prolonged duration on therapy greater than one year, longer than anticipated with standard therapy. In the aforementioned clinical trials, the mPFS was 10.6 months for patients receiving IFL plus bevacizumab in the first-line setting [4] and 5.7 months for patients in the trial evaluating FOLFIRI plus bevacizumab in the second-line setting. [6] Further analysis on archival specimens of these patients is warranted to determine if these tumors have any common molecular characteristics that could identify patients that may be appropriate for this dual VEGF inhibition.
The only patient who had not received prior systemic therapy for colon cancer has had a remarkable duration of disease stability with 78 cycles of treatment, which equates to 39 months or 3.25 years of progression-free survival. This surpasses the median overall survival times from recently reported clinical trials in metastatic colorectal cancer of approximately 30 months. [2, 21] Even more interesting is that the patient remains on all agents at dose level 2 of the regimen and continues to tolerate therapy quite well. The results of the Patients With Metastatic Colorectal Cancer Treated With Regorafenib Or Placebo After Failure Of Standard Therapy (CORRECT) study established a survival improvement of the novel kinase inhibitor regorafenib for patients that had progressed on fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and an EGFR inhibitor (if KRAS wild type). This led to FDA approval of regorafenib in September, 2012. Given the activity of regorafenib in the last line setting, there was no longer interest in developing sorafenib further in mCRC and therefore a randomized phase II study of FOLFIRI plus bevacizumab with or without sorafenib did not move forward.
While results of our phase I trial are intriguing, the role of dual VEGF inhibition with bevacizumab and sorafenib remains uncertain. After promising results of the phase I trial bevacizumab and sorafenib in advanced solid tumors reported Azad et al. [13] (bevacizumab 5 mg/kg every 2 weeks plus sorafenib 200 mg twice daily), subsequent trials have shown mixed results in terms of efficacy and tolerability of the combination. The aforementioned N054C trial for patients with mCRC after failure of standard agents, bevacizumab and sorafenib did show a promising disease control rate of 63 %. However, in the BeST trial for patients with metastatic renal cell carcinoma, the combination bevacizumab plus sorafenib arm was not superior to the bevacizumab alone arm. [22] Limited efficacy and high toxicity was reported evaluating the combination for breast, neuroendocrine, and hepatocellular carcinoma. [23] [24] [25] .
In conclusion, this phase I clinical trial demonstrated the safety of the combination of FOLFIRI, bevacizumab and sorafenib and identified the MTD of this regimen in patients with mCRC. Select patients had prolonged disease stabilization and remained on therapy for over a year. Further investigations are needed to identify which patients with mCRC may benefit from dual VEGF inhibition in combination with cytotoxic chemotherapy. Oxali oxaliplatin, FP fluoropyrimidine (5-fluorouracil or capecitabine), bev bevacizumab, EGFR epidermal growth factor receptor (cetuximab or panitumumab), XRT radiation therapy, SD stable disease, PR partial response, PD progressive disease
